Medtide Inc. (HKG:3880), a peptide-focused CRDMO, is experiencing a significant surge in its stock price during intraday trading on Monday. The company's shares are soaring 5.23%, marking a strong reversal from its initial performance at the market open.
This impressive rally comes on the heels of Medtide's recent initial public offering (IPO) in Hong Kong. The company successfully raised HK$428.8 million in net proceeds after pricing its shares at HK$30.60, the top end of the indicative price range. The IPO garnered substantial interest, with the Hong Kong public offer portion being 301.15 times oversubscribed, leading to a reallocation of shares from the international offering.
Despite opening slightly below its IPO price at HK$30.30 in early trading, investor sentiment appears to have shifted dramatically during the day. The strong intraday performance suggests growing confidence in Medtide's prospects and may reflect investors' positive reaction to the company's successful fundraising and the high demand seen during the IPO process. As the trading day progresses, market participants will be closely watching to see if this upward momentum can be sustained.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.